688062 迈威生物
交易中 02-10 11:01:57
资讯
新帖
简况
2月2日迈威生物创60日新低，易方达医疗保健行业混合A基金重仓该股
证券之星 · 02-02
2月2日迈威生物创60日新低，易方达医疗保健行业混合A基金重仓该股
迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，1月28日股价下跌1.95%
证券之星 · 01-28
迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，1月28日股价下跌1.95%
迈威生物：公司负责大中华区和东南亚区域的开发及商业化
证券日报 · 01-28
迈威生物：公司负责大中华区和东南亚区域的开发及商业化
股市必读：迈威生物（688062）预计2025年全年归属净利润亏损9亿元至9.95亿元
证券之星 · 01-26
股市必读：迈威生物（688062）预计2025年全年归属净利润亏损9亿元至9.95亿元
每周股票复盘：迈威生物（688062）预计2025年净亏9亿至9.95亿元
证券之星 · 01-25
每周股票复盘：迈威生物（688062）预计2025年净亏9亿至9.95亿元
迈威生物：预计2025年全年归属净利润亏损9亿元至9.95亿元
证券之星 · 01-23
迈威生物：预计2025年全年归属净利润亏损9亿元至9.95亿元
迈威生物宣布美国首例患者接受新型Cdh17靶向ADC药物7Mw4911临床试验给药
美股速递 · 01-22
迈威生物宣布美国首例患者接受新型Cdh17靶向ADC药物7Mw4911临床试验给药
迈威生物（688062）发布继续使用部分暂时闲置募集资金进行现金管理公告，1月21日股价下跌0.42%
证券之星 · 01-21
迈威生物（688062）发布继续使用部分暂时闲置募集资金进行现金管理公告，1月21日股价下跌0.42%
1月7日迈威生物涨9.55%，新华优选分红混合A基金重仓该股
证券之星 · 01-07
1月7日迈威生物涨9.55%，新华优选分红混合A基金重仓该股
迈威生物宣布抗IL-11抗体治疗病理性瘢痕二期临床试验首例患者完成给药
美股速递 · 2025-12-30
迈威生物宣布抗IL-11抗体治疗病理性瘢痕二期临床试验首例患者完成给药
每周股票复盘：迈威生物（688062）9MW1911获FDA许可拟美开展IIa期临床
证券之星 · 2025-12-28
每周股票复盘：迈威生物（688062）9MW1911获FDA许可拟美开展IIa期临床
迈威生物（688062）披露取消监事会及修订公司章程议案获股东大会通过，12月25日股价上涨0.9%
证券之星 · 2025-12-25
迈威生物（688062）披露取消监事会及修订公司章程议案获股东大会通过，12月25日股价上涨0.9%
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 2025-12-25
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
迈威生物（688062）披露股份回购实施结果公告，12月24日股价上涨0.99%
证券之星 · 2025-12-24
迈威生物（688062）披露股份回购实施结果公告，12月24日股价上涨0.99%
迈威生物(688062.SH)：9MW1911注射液临床试验申请获得FDA许可
智通财经 · 2025-12-23
迈威生物(688062.SH)：9MW1911注射液临床试验申请获得FDA许可
12月15日迈威生物跌6.05%，新华优选分红混合A基金重仓该股
证券之星 · 2025-12-15
12月15日迈威生物跌6.05%，新华优选分红混合A基金重仓该股
迈威生物宣布创新抗St2抗体9Mw1911的IIa期试验结果显示年严重 COPD 加重率降低超过 40%
美股速递 · 2025-12-01
迈威生物宣布创新抗St2抗体9Mw1911的IIa期试验结果显示年严重 COPD 加重率降低超过 40%
迈威生物（688062）自愿披露关于9MW1911临床研究进展的公告，12月1日股价下跌0.44%
证券之星 · 2025-12-01
迈威生物（688062）自愿披露关于9MW1911临床研究进展的公告，12月1日股价下跌0.44%
百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参
每日经济新闻 · 2025-12-01
百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参
迈威生物：9MW1911临床研究进展顺利COPD急性加重年化发生率显著降低
证券之星 · 2025-11-30
迈威生物：9MW1911临床研究进展顺利COPD急性加重年化发生率显著降低
加载更多
公司概况
公司名称：
迈威(上海)生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-18
主营业务：
迈威(上海)生物科技股份有限公司的主营业务是治疗用生物制品的研发、生产与销售。公司的主要产品是抗体药物、技术服务。
发行价格：
34.80
{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物","latestPrice":37.3,"timestamp":1770692517000,"preClose":36.3,"halted":0,"volume":4462210,"delay":0,"changeRate":0.0275,"floatShares":204000000,"shares":400000000,"eps":-2.3711,"marketStatus":"交易中","change":1,"latestTime":"02-10 11:01:57","open":36.5,"high":37.89,"low":36.15,"amount":166000000,"amplitude":0.0479,"askPrice":37.35,"askSize":2,"bidPrice":37.31,"bidSize":19,"shortable":0,"etf":0,"ttmEps":-2.3711,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770694200000},"marketStatusCode":2,"adr":0,"adjPreClose":36.3,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770687000000,1770694200000],[1770699600000,1770706800000]],"highLimit":39.93,"lowLimit":32.67,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":399600000,"isCdr":false,"pbRate":19.06,"roa":"--","roe":"--","epsLYR":-2.61,"committee":-0.325203,"marketValue":14905000000,"turnoverRate":0.0219,"status":0,"floatMarketCap":7616000000},"requestUrl":"/m/hq/s/688062","defaultTab":"news","newsList":[{"id":"2608851807","title":"2月2日迈威生物创60日新低，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608851807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608851807?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:40","pubTimestamp":1770021648,"startTime":"0","endTime":"0","summary":"证券之星消息，2月2日迈威生物创60日新低，收盘报34.78元，当日跌3.42%，换手率3.14%，成交量6.41万手，成交额2.27亿元。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共26家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为30.94亿元，最新净值3.96，较上一交易日下跌0.13%，近一年上涨33.15%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2606717868","title":"迈威生物（688062）披露关于调整部分募投项目内部投资结构的议案，1月28日股价下跌1.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606717868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606717868?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:14","pubTimestamp":1769609661,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，迈威生物报收于37.75元，较前一交易日下跌1.95%，最新总市值为150.85亿元。近日，迈威（上海）生物科技股份有限公司发布《2026年第一次临时股东会会议资料》公告，拟对2022年首次公开发行股份募投项目中的“抗体药物研发项目”内部投资结构进行调整，减少9MW0311、9MW0321、8MW0511、9MW1111、9MW1411、6MW3211项目的募集资金投入合计9,083.18万元，并将该部分资金用于增加9MW2821项目的投入。本次调整不涉及募投项目计划投入募集资金总额的变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2606167927","title":"迈威生物：公司负责大中华区和东南亚区域的开发及商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2606167927","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606167927?lang=zh_cn&edition=full","pubTime":"2026-01-28 20:11","pubTimestamp":1769602260,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月28日，迈威生物在互动平台回答投资者提问时表示，公司研发的重组抗TMPRSS6单克隆抗体创新药9MW3011为全球唯一一款用于真性红细胞增多症 治疗的靶向TMPRSS6单抗，该管线公司已经实现对外授权合作，公司负责大中华区和东南亚区域的开发及商业化，其他区域由合作伙伴DISCMEDICINE，INC.全面推进并先后获得美国FDA授予“快速通道认定”和“孤儿药资格认定”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-28/doc-inhiwnws4788037.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-28/doc-inhiwnws4788037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2606526595","title":"股市必读：迈威生物（688062）预计2025年全年归属净利润亏损9亿元至9.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606526595","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606526595?lang=zh_cn&edition=full","pubTime":"2026-01-26 03:16","pubTimestamp":1769368573,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，迈威生物报收于40.3元，上涨2.23%，换手率3.4%，成交量6.94万手，成交额2.81亿元。业绩披露要点业绩预告迈威生物发布业绩预告，预计2025年全年归属净利润亏损9亿元至9.95亿元；扣非后净利润亏损9.05亿元至9.99亿元。公司公告汇总迈威生物2025年年度业绩预告迈威生物预计2025年度归属于母公司所有者的净利润为-90,000.00万元到-99,450.00万元，扣除非经常性损益后净利润为-90,500.00万元到-99,950.00万元，较上年同期亏损收窄。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062"],"gpt_icon":0},{"id":"2606232739","title":"每周股票复盘：迈威生物（688062）预计2025年净亏9亿至9.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606232739","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606232739?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:13","pubTimestamp":1769281990,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，迈威生物报收于40.3元，较上周的43.24元下跌6.8%。本周，迈威生物1月19日盘中最高价报43.55元。本周关注点业绩披露要点：迈威生物预计2025年归属净利润亏损9亿元至9.95亿元。公司公告汇总：迈威生物拟继续使用不超过8亿元闲置募集资金进行现金管理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2605784354","title":"迈威生物：预计2025年全年归属净利润亏损9亿元至9.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605784354","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605784354?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:53","pubTimestamp":1769158404,"startTime":"0","endTime":"0","summary":"证券之星消息，迈威生物发布业绩预告，预计2025年全年归属净利润亏损9亿元至9.95亿元。迈威生物2025年三季报显示，前三季度公司主营收入5.66亿元，同比上升301.03%；归母净利润-5.98亿元，同比上升13.89%；扣非净利润-6.22亿元，同比上升12.91%；其中2025年第三季度，公司单季度主营收入4.65亿元，同比上升1717.41%；单季度归母净利润-4634.11万元，同比上升81.4%；单季度扣非净利润-4881.64万元，同比上升80.77%；负债率79.11%，投资收益-577.49万元，财务费用5837.5万元，毛利率93.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300027276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062"],"gpt_icon":0},{"id":"1126502808","title":"迈威生物宣布美国首例患者接受新型Cdh17靶向ADC药物7Mw4911临床试验给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1126502808","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126502808?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:07","pubTimestamp":1769090863,"startTime":"0","endTime":"0","summary":"迈威生物（Mabwell）宣布，其研发的新型靶向Cdh17的抗体偶联药物（ADC）7Mw4911已在美国完成首例患者临床试验给药。这一里程碑标志着该创新疗法正式进入临床研究阶段，为后续开发奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2605835104","title":"迈威生物（688062）发布继续使用部分暂时闲置募集资金进行现金管理公告，1月21日股价下跌0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605835104","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605835104?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:24","pubTimestamp":1769005464,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，迈威生物报收于40.01元，较前一交易日下跌0.42%，最新总市值为159.88亿元。近日，迈威生物发布公告称，公司于2026年1月21日召开董事会，审议通过继续使用不超过8亿元的暂时闲置募集资金进行现金管理，投资安全性高、流动性好、有保本约定的产品，使用期限为自董事会审议通过之日起12个月内，资金可循环滚动使用。保荐机构对本次现金管理事项无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100040911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2601141827","title":"1月7日迈威生物涨9.55%，新华优选分红混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601141827","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601141827?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:33","pubTimestamp":1767771216,"startTime":"0","endTime":"0","summary":"证券之星消息，1月7日迈威生物涨9.55%，收盘报45.2元，换手率7.52%，成交量15.35万手，成交额6.78亿元。重仓迈威生物的前十大公募基金请见下表：该股最近90天内共有7家机构给出评级，买入评级5家，增持评级2家；过去90天内机构目标均价为55.42。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共26家，其中持有数量最多的公募基金为新华基金的新华优选分红混合A。该公募基金现任基金经理为赵强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700017945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"1159975946","title":"迈威生物宣布抗IL-11抗体治疗病理性瘢痕二期临床试验首例患者完成给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1159975946","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159975946?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:03","pubTimestamp":1767103387,"startTime":"0","endTime":"0","summary":"迈威生物宣布，其针对病理性瘢痕开发的抗IL-11抗体药物二期临床试验已顺利完成首例患者给药。该试验旨在评估该创新疗法在改善瘢痕形成方面的安全性与有效性，标志着公司在自身免疫及纤维化疾病领域取得重要进展。此次临床推进为后续研究奠定了关键基础，有望为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2594244551","title":"每周股票复盘：迈威生物（688062）9MW1911获FDA许可拟美开展IIa期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2594244551","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594244551?lang=zh_cn&edition=full","pubTime":"2025-12-28 02:29","pubTimestamp":1766860149,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，迈威生物报收于39.94元，较上周的39.61元上涨0.83%。本周关注点公司公告汇总：9MW1911注射液临床试验申请获FDA许可，拟在美国开展针对中重度COPD患者的IIa期临床研究。该药品为自主开发的抗ST2单克隆抗体，已在境内完成IIa期临床试验，安全性良好，药代动力学和初步疗效数据支持进一步开发。目前IIb期临床试验正在积极入组，计划2026年底启动III期研究。表决程序合法，表决结果有效。董事会成员仍为9名，符合相关法规要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2594237416","title":"迈威生物（688062）披露取消监事会及修订公司章程议案获股东大会通过，12月25日股价上涨0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594237416","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594237416?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:33","pubTimestamp":1766673197,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，迈威生物报收于40.2元，较前一交易日上涨0.9%，最新总市值为160.64亿元。近日，迈威（上海）生物科技股份有限公司召开2025年第三次临时股东大会，审议通过了《关于取消监事会、修订〈公司章程〉及相关议事规则的议案》及《关于修订部分公司治理制度的议案》。其中，取消监事会及修订公司章程为特别决议议案，已获出席股东所持表决权2/3以上通过；其余治理制度修订为普通决议议案，获1/2以上通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500036210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688428","BK0060","01801","LU2580892862.HKD","02096","BK1161","LU0405327148.USD","BK0028","02142","688336","688331","BK1589","LU2097828474.EUR","LU1997244956.HKD","LU1781817850.SGD","01530","000661","002755","600276","LU2148510915.USD","LU1064130708.USD","LU1997245177.USD","BK0012","LU2488822045.USD","BK0196","BK0239","LU0405327494.USD","03692","BK1574","BK1593","BK0057","688062","09995","BK0188","LU0502904849.HKD","LU1969619763.USD","LU2097828557.USD","01167","LU2097828631.EUR","02509","BK0183","LU1328615791.USD","LU2495084118.USD","06978","603087","LU1064131003.USD","LU1997245094.SGD","LU2097828714.EUR","LU2097828805.USD","LU1146622755.USD"],"gpt_icon":0},{"id":"2593475668","title":"迈威生物（688062）披露股份回购实施结果公告，12月24日股价上涨0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593475668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593475668?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:51","pubTimestamp":1766569908,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，迈威生物报收于39.84元，较前一交易日上涨0.99%，最新总市值为159.2亿元。该股当日开盘39.84元，最高40.7元，最低39.46元，成交额达2.14亿元，换手率为2.63%。公司近日发布公告称，迈威生物于2025年6月26日启动股份回购，回购期限为12个月，回购资金总额预计2,500万元至5,000万元，回购价格上限调整为66.46元/股。回购股份将用于员工持股计划或股权激励，目前存放于回购专用证券账户，不影响公司控制权及上市地位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400029043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2593649030","title":"迈威生物(688062.SH)：9MW1911注射液临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2593649030","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593649030?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:51","pubTimestamp":1766494262,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到美国食品药品监督管理局(FDA)签发的《临床研究继续进行通知书》(Study May Proceed Notification)，9MW1911注射液临床试验申请正式获得FDA许可。9MW1911为一款基于高效B淋巴细胞筛选平台自主研发的创新单克隆抗体，属于治疗用生物制品1类，可高亲和力结合ST2受体，从而阻断IL33/ST2 信号通路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"迈威生物(688062.SH)：9MW1911注射液临床试验申请获得FDA许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2591615393","title":"12月15日迈威生物跌6.05%，新华优选分红混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591615393","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591615393?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:34","pubTimestamp":1765784042,"startTime":"0","endTime":"0","summary":"证券之星消息，12月15日迈威生物跌6.05%创60日新低，收盘报38.33元，换手率4.35%，成交量8.87万手，成交额3.47亿元。重仓迈威生物的前十大公募基金请见下表：该股最近90天内共有8家机构给出评级，买入评级6家，增持评级2家；过去90天内机构目标均价为56.03。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共26家，其中持有数量最多的公募基金为新华基金的新华优选分红混合A。该公募基金现任基金经理为赵强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"1152178837","title":"迈威生物宣布创新抗St2抗体9Mw1911的IIa期试验结果显示年严重 COPD 加重率降低超过 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152178837","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152178837?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:01","pubTimestamp":1764597675,"startTime":"0","endTime":"0","summary":"迈威生物宣布其创新抗St2抗体9Mw1911的IIa期试验结果，年严重COPD加重率降低超过40%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2588253057","title":"迈威生物（688062）自愿披露关于9MW1911临床研究进展的公告，12月1日股价下跌0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588253057","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588253057?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:48","pubTimestamp":1764582534,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，迈威生物报收于42.91元，较前一交易日下跌0.44%，最新总市值为171.47亿元。近日，迈威生物发布自愿披露关于9MW1911临床研究进展的公告。研究结果显示，9MW1911各剂量组安全性与耐受性良好，不良事件发生率与安慰剂组相近，免疫原性均为阴性。在推荐剂量下，中重度COPD急性加重年化发生率较安慰剂组降低超30%，重度急性加重年化发生率降低超40%，且发生重度急性加重的患者比例显著降低。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100022929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2588371664","title":"百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588371664","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588371664?lang=zh_cn&edition=full","pubTime":"2025-12-01 07:13","pubTimestamp":1764544408,"startTime":"0","endTime":"0","summary":"｜2025年12月1日星期一｜NO.1百利天恒收到百时美施贵宝里程碑付款百利天恒公告，子公司SystImmune已收到由百时美施贵宝支付的2.5亿美元里程碑付款。据合作协议，公司后续还有资格获得最高可达2.5亿美元的近期或有付款，以及在达到特定的开发、注册和销售里程碑后最高可达71亿美元的额外付款。合作协议中所约定的里程碑付款需要满足一定的条件，最终里程碑付款尚存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512013578546745.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512013578546745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","688062","BK1574","688506","BK1161","02615","159938","BK0239","09939","91194"],"gpt_icon":0},{"id":"2587716796","title":"迈威生物：9MW1911临床研究进展顺利COPD急性加重年化发生率显著降低","url":"https://stock-news.laohu8.com/highlight/detail?id=2587716796","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587716796?lang=zh_cn&edition=full","pubTime":"2025-11-30 16:11","pubTimestamp":1764490269,"startTime":"0","endTime":"0","summary":"迈威生物(688062.SH)公告称，公司自主研发的创新药9MW1911 已完成在中重度慢性阻塞性肺疾病（COPD）患者中的IIa 期临床研究，所有剂量组均表现出良好的安全性与耐受性。在IIb 期研究推荐剂量下，中重度COPD 急性加重年化发生率较安慰剂组降低超30%，重度急性加重年化发生率降低超40%，且发生重度急性加重的患者比例显著降低。目前，公司正在积极推进9MW1911 在COPD 适应症开展的IIb 期临床研究。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025113000002386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770692528573,"stockEarnings":[{"period":"1week","weight":0.0437},{"period":"1month","weight":-0.2069},{"period":"3month","weight":-0.1451},{"period":"6month","weight":0.0134},{"period":"1year","weight":1.1973},{"period":"ytd","weight":-0.0564}],"compareEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0301},{"period":"6month","weight":0.1194},{"period":"1year","weight":0.248},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19583人(较上一季度增加9.15%)","perCapita":"10425股","listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","registeredCapital":"39960万元","survey":" 迈威(上海)生物科技股份有限公司的主营业务是治疗用生物制品的研发、生产与销售。公司的主要产品是抗体药物、技术服务。","listedPrice":34.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物,688062,迈威生物股票,迈威生物股票老虎,迈威生物股票老虎国际,迈威生物行情,迈威生物股票行情,迈威生物股价,迈威生物股市,迈威生物股票价格,迈威生物股票交易,迈威生物股票购买,迈威生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}